Recent studies have suggested that blocking VEGF/VEGF receptor 2 (VERFR2) signaling can transiently normalize the tumor vasculature and increase the number of intratumoral CD8+ T cells 28-32. The gene discussed is CD8A; the disease is neoplasm.